The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance
Open accessAbstract
The molecular mechanism by which cancer-associated fibroblasts (CAFs) confer chemoresistance in ovarian cancer is poorly understood. The purpose of the present study was to evaluate the roles of CAFs in modulating tumor vasculature, chemoresistance, and disease progression. Here, we found that CAFs upregulated the lipoma-preferred partner (LPP) gene in microvascular endothelial cells (MECs) and that LPP expression levels in intratumoral MECs correlated with survival and chemoresistance in patients with ovarian cancer. Mechanistically, LPP increased focal adhesion and stress fiber formation to promote endothelial cell motility and permeability. siRNA-mediated LPP silencing in ovarian tumor-bearing mice improved paclitaxel delivery to cancer cells by decreasing intratumoral microvessel leakiness. Further studies showed that CAFs regulate endothelial LPP via a calcium-dependent signaling pathway involving microfibrillar-associated protein 5 (MFAP5), focal adhesion kinase (FAK), ERK, and LPP. Thus, our findings suggest that targeting endothelial LPP enhances the efficacy of chemotherapy in ovarian cancer. Our data highlight the importance of CAF-endothelial cell crosstalk signaling in cancer chemoresistance and demonstrate the improved efficacy of using LPP-targeting siRNA in combination with cytotoxic drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since excessive fibrosis also acts as the obstacle of obtaining anticancer effects from drug treatments,[ 37 ]”
From Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling (2021) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“Blood vessels in tumor tissue are usually poorly organized and leaky, which impairs drug delivery (17).”
BackgroundModes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · cited 1×
“However, several clinical trials in cancer patients have demonstrated that agents targeting VEGF family members convey a progression-free survival advantage but rarely an overall survival advantage, possibly because other potent proangiogenic factors and their downstream effector molecules are present in the tumor mic…”
BackgroundA Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, É., Kristensen, G. B., Carey, M. S., Beale, P. J., Cervantes, A. M. R., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,181
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116 · cited 1×
“Despite a severely defective barrier function and increase in diameter, tumor vessels do not facilitate drug delivery, because their high interstitial pressure limits the extravasation of fluid and macromolecules (36, 37).”
BackgroundFriends or foes — bipolar effects of the tumour stroma in cancer
Mueller, M. M., & Fusenig, N. E. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1477 · Cited by 1,817
Openings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689
Pujade-Lauraine, É., Hilpert, F., Weber, B. E., Reuß, A., Poveda, A. M., Kristensen, G. B., Sorio, R., Vergote, I. B., Witteveen, P. O., Bamias, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4489 · Cited by 1,660
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
Aghajanian, C. A., Blank, S. V., Goff, B. A., Judson, P. L., Teneriello, M. G., Husain, A., Sovak, M. A., Yi, J., & Nycum, L. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.0505 · Cited by 1,384
Ingber, D. E., & Folkman, J. (1989) · The Journal of Cell Biology · doi:10.1083/jcb.109.1.317 · Cited by 870
Cited by
Sorted by citations
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773
Cancer-associated fibroblasts in gastrointestinal cancer
Kobayashi, H., Enomoto, A., Woods, S. L., Burt, A. D., Takahashi, M., & Worthley, D. L. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0115-0 · Cited by 609
Transforming Growth Factor-β Signaling in Fibrotic Diseases and Cancer-Associated Fibroblasts
Shi, X., Young, C. D., Zhou, H., & Wang, X. (2020) · Biomolecules · doi:10.3390/biom10121666 · Cited by 269
Targeting tumor microenvironment in ovarian cancer: Premise and promise
Jiang, Y., Wang, C., & Zhou, S. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188361 · Cited by 235
Fang, Y., Zhou, W., Rong, Y., Kuang, T., Xu, X., Wu, W., Wang, D., & Lou, W. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.111543 · Cited by 223
Cancer-associated fibroblasts: Origin, function, imaging, and therapeutic targeting
Rimal, R., Desai, P. B., Daware, R., Hosseinnejad, A., Prakash, J., Lammers, T., & Singh, S. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114504 · Cited by 210
Contribution of regulatory T cells to cancer: A review
Najafi, M., Farhood, B., & Mortezaee, K. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27553 · Cited by 193
Tumor evolution and chemoresistance in ovarian cancer
Kim, S., Han, Y., Kim, S. I., Kim, H., Kim, S. J., & Song, Y. S. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0063-0 · Cited by 188
The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment
Ni, Y., Zhou, X., Yang, J., Shi, H., Li, H., Zhao, X., & Ma, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.637675 · Cited by 184
ERK is a Pivotal Player of Chemo-Immune-Resistance in Cancer
Salaroglio, I. C., Mungo, E., Gazzano, E., Kopecka, J., & Riganti, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102505 · Cited by 159
Cancer-Associated Fibroblasts: Understanding Their Heterogeneity
Louault, K., Li, R., & DeClerck, Y. A. (2020) · Cancers · doi:10.3390/cancers12113108 · Cited by 162
Rodriguez, G. M., Galpin, K. J. C., McCloskey, C. W., & Vanderhyden, B. C. (2018) · Cancers · doi:10.3390/cancers10080242 · Cited by 141
Cancer-associated fibroblasts in radiotherapy: challenges and new opportunities
Wang, Z., Tang, Y., Tan, Y., Wei, Q., & Yu, W. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0362-2 · Cited by 142
Cancer-Associated Fibroblasts: Versatile Players in the Tumor Microenvironment
Ganguly, D., Chandra, R., Karalis, J. D., Teke, M. E., Aguilera, T. A., Maddipati, R., Wachsmann, M., Ghersi, D., Siravegna, G., Zeh, H. J., et al. (2020) · Cancers · doi:10.3390/cancers12092652 · Cited by 130
Cancer‐associated fibroblasts: Secretions, interactions, and therapy
Farhood, B., Najafi, M., & Mortezaee, K. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27703 · Cited by 109
The Calcium-Signaling Toolkit in Cancer: Remodeling and TargetingPreprint
Roberts‐Thomson, S. J., Chalmers, S. B., & Monteith, G. R. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a035204 · Cited by 112
Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment
Drakes, M. L., & Stiff, P. J. (2018) · Cancers · doi:10.3390/cancers10090302 · Cited by 115
Cancer Associated Fibroblasts: Naughty Neighbors That Drive Ovarian Cancer Progression
Dasari, S., Fang, Y., & Mitra, A. K. (2018) · Cancers · doi:10.3390/cancers10110406 · Cited by 102
Li, Z., Pai, R., Gupta, S., Currenti, J., Guo, W., Bartolomeo, A. D., Feng, H., Zhang, Z., Li, Z., Liu, L., et al. (2024) · Nature Cancer · doi:10.1038/s43018-023-00672-2 · Cited by 107
Calcium signalling and breast cancer
So, C. L., Saunus, J. M., Roberts‐Thomson, S. J., & Monteith, G. R. (2018) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2018.11.001 · Cited by 91
The interactions of paclitaxel with tumour microenvironment
Yu, D., Lou, Z., Ma, F.-Y., & Najafi, M. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108555 · Cited by 93
Zhang, B., Zhang, Y., Zhang, J., Liu, P., Jiao, B., Wang, Z., & Ren, R. (2021) · Advanced Science · doi:10.1002/advs.202100250 · Cited by 83
Chen, S., Yang, M., Wang, C., Ouyang, Y., Chen, X., Bai, J., Hu, Y., Song, M., Zhang, S., & Zhang, Q. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.046 · Cited by 77
Yeung, T.-L., Leung, C. S., Yip, K., Sheng, J., Vien, L., Bover, L. C., Birrer, M. J., Wong, S. T. C., & Mok, S. C. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0187 · Cited by 77
Self-citationThe importance of being CAFs (in cancer resistance to targeted therapies)
Rizzolio, S., Giordano, S., & Corso, S. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02524-w · Cited by 75
Zhang, T., Zhang, P., & Li, H.-X. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s271976 · Cited by 71
Potential mechanisms of cancer-associated fibroblasts in therapeutic resistance
Zhao, Z., Li, T., Sun, L. L., Yuan, Y., & Zhu, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115425 · Cited by 71
Targeting the tumour microenvironment in platinum-resistant ovarian cancer
Cummings, M., Freer, C., & Orsi, N. M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.007 · Cited by 65
Ghoneum, A., Afify, H. M. A., Salih, Z. T., Kelly, M., & Said, N. A. (2018) · Cancer Medicine · doi:10.1002/cam4.1741 · Cited by 57
Jung, W., Yam, N., Chen, C.-C., Elawad, K., Hu, B., & Chen, Y. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119756 · Cited by 58
Li, Y., Chen, Y., Miao, L., Wang, Y., Yu, M., Yan, X., Zhao, Q., Cai, H., Xiao, Y., & Huang, G. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.10.032 · Cited by 58
3D Cancer Models: Depicting Cellular Crosstalk within the Tumour Microenvironment
Franchi-Mendes, T., Eduardo, R., Domenici, G., & Brito, C. (2021) · Cancers · doi:10.3390/cancers13184610 · Cited by 59
Immunological configuration of ovarian carcinoma: features and impact on disease outcome
Fucikova, J. P., Coosemans, A., Oršulić, S., Cibula, D., Vergote, I. B., Galluzzi, L., & Špíšek, R. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002873 · Cited by 55
Wang, T., Xu, C., Zhang, Z., Wu, H. J., Li, X., Zhang, Y., Deng, N., Dang, N., Tang, G., Yang, X., et al. (2022) · Hepatology · doi:10.1002/hep.32483 · Cited by 52
Park, S., Jung, W., Pittman, M., Chen, J., & Chen, Y. (2020) · Journal of Biomechanical Engineering · doi:10.1115/1.4048110 · Cited by 54
Cancer-Associated Fibroblast Functions as a Road-Block in Cancer Therapy
De, P. K., Aske, J. C., & Dey, N. (2021) · Cancers · doi:10.3390/cancers13205246 · Cited by 54
Wang, B., Liu, W., Liu, C., Du, K., Guo, Z., Zhang, G., Huang, Z., Lin, S., Cen, B., Tian, Y., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.12.029 · Cited by 54
Quinn, J. M., Greenwade, M. M., Palisoul, M. L., Opara, G., Massad, K., Guo, L., Zhao, P., Beck-Noia, H., Hagemann, I. S., Hagemann, A. R., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0537 · Cited by 52
Wu, Z., Wang, T., Fang, M., Huang, W., Sun, Z., Xiao, J., & Yan, W. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.03.007 · Cited by 49
Chitosan-based nanotherapeutics for ovarian cancer treatment
Alizadeh, L., Zarebkohan, A., Salehi, R., Ajoolabady, A., & Rahmati‐Yamchi, M. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1564923 · Cited by 46
Duan, Y., Zhang, X., Ying, H., Xu, J., Yang, H., Sun, K., He, L., Li, M., Ji, Y., Liang, T., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02711-9 · Cited by 46
Ding, Q., Dong, S., Wang, R., Zhang, K., Wang, H., Zhou, X., Wang, J., Wong, K., Long, Y., Zhu, S., et al. (2020) · Aging · doi:10.18632/aging.102914 · Cited by 46
Self-citationGao, Q., Fang, X., Chen, Y., Li, Z., & Wang, M. (2020) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.14418 · Cited by 45
Insights into the antitumor mechanism of ginsenosides Rg3
Liu, Z., Liu, T., Li, W., Li, J., Wang, C., & Zhang, K. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06187-2 · Cited by 42
Li, J., Zhu, X., Li, F.-X., Huang, C., Huang, X., Wang, J., Gao, Z., Li, S., Xu, Q., Zhao, W., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1477-4 · Cited by 40
Direct signaling of TL1A-DR3 on fibroblasts induces intestinal fibrosis in vivo
Jacob, N., Kumagai, K., Abraham, J. P., Shimodaira, Y., Ye, Y., Luu, J., Blackwood, A. Y., Castanon, S. L., Stamps, D. T., Thomas, L. S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-75168-5 · Cited by 39
Zhang, K., Zhai, Z., Yu, S., & Tao, Y. (2021) · Journal of Cancer · doi:10.7150/jca.52338 · Cited by 38
Epigenetic regulation and therapeutic targets in the tumor microenvironment
Xie, Z., Zhou, Z., Yang, S., Zhang, S., & Shao, B. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00126-2 · Cited by 38
Liu, C.-L., Pan, H., Torng, P., Fan, M. H., & Mao, T. L. (2019) · Oncology Reports · doi:10.3892/or.2019.7379 · Cited by 37
Chen, C., Hou, J., Yu, S., Li, W., Wang, X., Sun, H., Qin, T., Claret, F. X., Guo, H., & Liu, Z. (2021) · Oncology Letters · doi:10.3892/ol.2021.12674 · Cited by 35
Role of tumor microenvironment in ovarian cancer metastasis and clinical advancements
Wang, Y., Zhu, N., Liu, J., Chen, F., Song, Y., Ma, Y., Yang, Z., & Wang, D. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06508-0 · Cited by 44
Stress responses in stromal cells and tumor homeostasis
Vitale, I., Manic, G., Galassi, C., & Galluzzi, L. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.004 · Cited by 33
Ding, H., Zhang, J., Zhang, F., Xu, Y., Yu, Y., Liang, W., & Li, Q. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109052 · Cited by 32
Bilbao, M., Aikins, J. K., & Ostrovsky, O. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.12.033 · Cited by 31
Gao, P., Peng, T., Cao, C., Lin, S., Wu, P., Huang, X., Wei, J., Xi, L., Qin, Y., & Wu, P. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.595436 · Cited by 28
Hu, X., Peng, X., Zhang, Y., Fan, S., Liu, X., Song, Y., Ren, S., Chen, L., Chen, Y., Wang, R., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155214 · Cited by 29
Stanniocalcin 1 in tumor microenvironment promotes metastasis of ovarian cancer
Yang, Y., Yin, S., Li, S., Chen, Y., & Yang, L. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s196150 · Cited by 28
Leptin contributes to the taxol chemoresistance in epithelial ovarian cancer
Gu, F., Zhang, H., Yao, L., Jiang, S., Lu, H., Xing, X., Zhang, C., Jiang, P., & Zhang, R. (2019) · Oncology Letters · doi:10.3892/ol.2019.10381 · Cited by 28
Bête Noire of Chemotherapy and Targeted Therapy: CAF-Mediated Resistance
De, P. K., Aske, J. C., Sulaiman, R. A., & Dey, N. (2022) · Cancers · doi:10.3390/cancers14061519 · Cited by 29
Iwagoi, Y., Motohara, T., Hwang, S., Fujimoto, K., Ikeda, T., & Katabuchi, H. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-01866-3 · Cited by 27
Sulaiman, R. A., De, P. K. R., Aske, J. C., Lin, X., Dale, A., Koirala, N., Gaster, K., Espaillat, L. R., Starks, D. C., & Dey, N. (2023) · Biomedicines · doi:10.3390/biomedicines11010112 · Cited by 27
Cold atmospheric plasma: Novel opportunities for tumor microenvironment targeting
Dai, X., & Zhu, K. (2023) · Cancer Medicine · doi:10.1002/cam4.5491 · Cited by 28
Wang, M., Li, X., Zhang, M., Ye, Q.-Y., Chen, Y.-X., & Xu, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.738534 · Cited by 27
Schuster, S. L., Arora, S., Wladyka, C. L., Itagi, P., Corey, L., Young, D., Stackhouse, B. L., Kollath, L. A., Wu, Q. V., Corey, E., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112840 · Cited by 28
Ye, Y., Zhang, S., Jiang, Y., Huang, Y., Wang, G., Zhang, M., Gui, Z., Wu, Y., Bian, G., Li, P., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-48653-w · Cited by 25
Nunes, M., Bartosch, C., Abreu, M. H., Richardson, A., Almeida, R., & Ricardo, S. A. V. (2024) · Cells · doi:10.3390/cells13090786 · Cited by 26
Zhang, X., Wang, Y., Cui, W., Li, D., Song, J., Liu, Y., Liu, Y., & Yang, S. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101273 · Cited by 26
Strategies for Delivery of siRNAs to Ovarian Cancer Cells
Farra, R., Maruna, M., Perrone, F. M., Grassi, M., Benedetti, F. M., Maddaloni, M., Boustani, M. E., Parisi, S., Rizzolio, F., Forte, G., et al. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11100547 · Cited by 23
The Effects of Chemotherapeutics on the Ovarian Cancer Microenvironment
Eckert, M. A., Orozco, C. A., Xiao, J. F., Javellana, M., & Lengyel, E. R. (2021) · Cancers · doi:10.3390/cancers13133136 · Cited by 23
CAFs vs. TECs: when blood feuds fuel cancer progression, dissemination and therapeutic resistance
Coursier, D., & Calvo, F. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00931-z · Cited by 23
Microengineered 3D Tumor Models for Anti-Cancer Drug Discovery in Female-Related Cancers
Amirghasemi, F., Adjei‐Sowah, E., Pockaj, B. A., & Nikkhah, M. (2021) · Annals of Biomedical Engineering · doi:10.1007/s10439-020-02704-9 · Cited by 25
Heterotypic signaling of cancer-associated fibroblasts in shaping the cancer cell drug resistance
Butti, R., Khaladkar, A., Bhardwaj, P., & Prakasam, G. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2022.72 · Cited by 23
Horowitz, M. P., Esakov, E. L., Rose, P. G., & Reizes, O. (2020) · Annals of Translational Medicine · doi:10.21037/atm-2019-cm-08 · Cited by 21
Microfibril-associated protein 5 and the regulation of skin scar formation
Chen, H., Leonardo, T. R., Romana‐Souza, B., Shi, J., Keiser, S., Yuan, H., Altakriti, M., Ranzer, M. J., Borgogno, S. F., Mok, S. C., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-35558-x · Cited by 20
Self-citationRoscigno, G., Scognamiglio, I., Ingenito, F., Chianese, R. V., Palma, F., Chan, A. B., & Condorelli, G. (2020) · Cancers · doi:10.3390/cancers12123744 · Cited by 20
A New Antitumor Direction: Tumor-Specific Endothelial Cells
Liang, J., Wang, S., Zhang, G., He, B., Bie, Q., & Zhang, B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.756334 · Cited by 18
Photon- and Proton-Mediated Biological Effects: What Has Been Learned?
Jumaniyazova, E. D., Смык, Д., Vishnyakova, P., Fatkhudinov, T., & Gordon, K. B. (2022) · Life · doi:10.3390/life13010030 · Cited by 18
Identifying gene expression patterns associated with drug-specific survival in cancer patients
Neary, B., Zhou, J., & Qiu, P. (2021) · Scientific Reports · doi:10.1038/s41598-021-84211-y · Cited by 17
Veith, I., Mencattini, A., Picant, V., Serra, M., Leclerc, M., Comes, M. C., Mami‐Chouaib, F., Camonis, J., Descroix, S., Shirvani, H., et al. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008870 · Cited by 16
Plesselova, S., Calar, K., Axemaker, H., Sahly, E., Bhagia, A., Faragher, J. L., Fink, D. M., & de la Puente, P. (2024) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-024-00817-y · Cited by 18
Lapuente-Santana, Ó., Kant, J., & Eduati, F. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00749-w · Cited by 17
CAF-mediated tumor vascularization: From mechanistic insights to targeted therapies
Zhang, Z., Zhang, Q. H., & Wang, Y. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111827 · Cited by 17
Loss of microfibril-associated protein 5 (MFAP5) expression in colon cancer stroma
Zhao, L., Westerhoff, M. A., Hornick, J. L., Krausz, T. N., Antic, T., Xiao, S., & Hart, J. A. L. (2019) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-019-02649-y · Cited by 15
Chung, K. P. S., Leung, R. W. H., & Lee, T. K. (2021) · Cancers · doi:10.3390/cancers13133191 · Cited by 14
Wang, H., Wu, J., Ling, R., Li, F., Yang, Q., He, J., Lei, X., Wu, C., Zhang, G., Zheng, B., et al. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.01.008 · Cited by 14
Han, L., Guo, X., Du, R., Guo, K., Qi, P., & Bian, H. (2022) · Journal of Ovarian Research · doi:10.1186/s13048-022-01003-2 · Cited by 14
Tokhanbigli, S., Haghi, M., Dua, K., & Oliver, B. G. G. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2024.55 · Cited by 14
Li, M., Zhang, Q., & Huang, X. (2021) · Cancer Management and Research · doi:10.2147/cmar.s319312 · Cited by 13
Dong, X., Yin, J.-X., Zhang, H., & Liao, Y. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.02.077 · Cited by 13
Jin, Y., Yang, S., Gao, X., Chen, D., Luo, T., Su, S., Shi, Y., Yang, G., Dong, L., & Liang, J. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.836199 · Cited by 13
Yan, S., Sun, R., Wu, S., Jin, T., Zhang, S., Niu, F., Li, J., & Chen, M. (2019) · BMC Cancer · doi:10.1186/s12885-018-5241-5 · Cited by 13
Cheon, I., Lee, S., Oh, S., & Ahn, Y. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102194 · Cited by 12
Cancer-associated fibroblasts in ovarian cancer: research progress
Xu, Y., Sun, D., He, J., & Yao, Q. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1504762 · Cited by 12
Cancer-associated fibroblasts in gynecological malignancies: are they really allies of the enemy?
Villegas‐Pineda, J. C., Ramírez-de-Arellano, A., Bueno-Urquiza, L. J., Lizarazo-Taborda, M. D. R., & Pereira-Suárez, A. L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1106757 · Cited by 13
Li, J., Wu, X. F., Ni, X., Li, Y.-X., Xu, L., Hao, X., Zhao, W., Zhu, X., & Yin, X. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1213 · Cited by 11
Wojtowicz, K., & Nowicki, M. O. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.04.059 · Cited by 14
Ma, Q., Kang, R., Xu, R., Guan, Y., Chang, S., & Li, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1614815 · Cited by 11
Cong, S., Guo, Q., Cheng, Y., He, Y., Zhao, X., Kong, C., Ning, S., & Zhang, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.614139 · Cited by 10
Wang, Y., Zhang, L., Bai, Y., Wang, L., & Ma, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1036298 · Cited by 9
Application Of Adoptive Immunotherapy In Ovarian Cancer
Yang, S., Yin, X., Yue, Y., & Wang, S. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s221773 · Cited by 12
Metadata
- Authors
- Leung, C. S., Yeung, T.-L., Yip, K.-P., Wong, K.-K., Ho, S. Y., Mangala, L. S., Sood, A. K., Lopez-Berestein, G., Sheng, J., Wong, S. T. C., Birrer, M. J., & Mok, S. C.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- University of South Florida (US)
- Houston Methodist Research Institute (US)
- University of Alabama at Birmingham (US)
- Corresponding author
- Birrer, Michael J.
- Mok, Samuel C.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2017-12-18
- Volume
- 128
- Issue
- 2
- Pages
- 589-606
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5785271
- OpenAlex
- W2774854449
- Cited by
- 132
- References
- 44
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 14 · 2023: 16 · 2022: 16 · 2021: 23 · 2020: 17 · 2019: 18 · 2018: 12
- FWCI
- 14.92
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (R01CA133057, R01CA142832, RC4CA156551, U54CA151668, P50CA083639, P50CA098258)
- Cancer Prevention and Research Institute of Texas (RP100094, RP110595)
- U.S. Department of Defense (W81XWH-17-1-0126, W81XWH-16-2-0038)
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- cancer-associated fibroblasts, ovarian cancer, chemoresistance, LPP, endothelial cells, tumor vasculature, endothelial cell motility, focal adhesions, calcium signaling, MFAP5, focal adhesion kinase, ERK, paclitaxel delivery, siRNA therapeutics
- MeSH terms
- Cancer-Associated Fibroblasts, Animals, Cell Movement, Cytoskeletal Proteins, Female, Fibrosis, Humans, Microcirculation, Neovascularization, Pathologic, Ovarian Neoplasms, Permeability, Signal Transduction, Up-Regulation, Gene Expression Regulation, Neoplastic, Treatment Outcome, Disease Progression, Drug Resistance, Neoplasm, Gene Silencing, Gene Expression Profiling, Focal Adhesions, RNA, Small Interfering, Endothelial Cells, Cell Line, Tumor, Mice, LIM Domain Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
